CTOs on the Move

Q32 Bio

www.q32bio.com

 
Q32 Bio is a biotechnology company developing therapeutics targeting powerful regulators of the innate and adaptive immune systems, with the goal of re-balancing the immune system in severe autoimmune and inflammatory diseases. Focused on the IL-7 pathway and complement system, Q32 Bio is addressing dysregulation to help patients take back control of their lives in diseases with few to no treatment options, or those diseases where current therapeutics provide inadequate relief.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.q32bio.com
  • 830 Winter Street
    Waltham, MA USA 02451
  • Phone: 781.999.0232

Executives

Name Title Contact Details
Saul Fink
Chief Technology Officer Profile

Funding

Q32 Bio raised $46M on 05/27/2020
Q32 Bio raised $60M on 10/29/2020

Similar Companies

Synthes

Synthes is a leading global medical device company. Through its five product groups (Trauma, Spine, Cranio-Maxillofacial, Biomaterials and Power Tools) it develops, produces and markets instruments, implants and biomaterials for the surgical fixation, correction and regeneration of the human skeleton and its soft tissues.

Acasti Pharma

Acasti Pharma Inc. is an emerging biopharmaceutical company dedicated to the research, development and commercialization of innovative proprietary active pharmaceutical ingredients (API) for the management of cardiometabolic disorders, from prevention to treatment, through a novel superior approach to lipid regulation. To carry out this mission, Acasti is advancing its portfolio of bioactive ingredients, by purifying and concentrating krill-oil extracts through innovative technology, to produce products targeting the prescription drug and medical food markets.

Zacharon

Zacharon is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pascal Biosciences

Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company`s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. Pascal is headquartered in Vancouver, Canada. The company trades on the TSX Venture Exchange under the symbol “PAS”.

Micell Technologies

Micell Technologies Inc is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.